ＴＩＰ３０表达与小细胞肺癌临床病理特征及预后的关系

目的　探讨肿瘤转移抑制基因ＴＩＰ３０的表达与小细胞肺癌（ＳＣＬＣ）临床病理特征及预后的关系。方法　采用免疫组织化学ＥｎＶｉｓｉｏｎ二步法检测５４例ＳＣＬＣ组织和４２例ＳＣＬＣ癌旁组织ＴＩＰ３０的表达情况。结果　ＴＩＰ３０在ＳＣＬＣ组织和癌旁组织中的阳性率分别为８０.９５％和４６.２９％，差异有统计学意义（Ｐ＜０.０５）；ＴＩＰ３０的表达与患者性别、年龄和吸烟情况无关，与临床分期、淋巴结转移、复发和远处转移有关。５４例ＳＣＬＣ患者的中位总生存期为１５.４个月；ＴＩＰ３０阳性表达者为２６.６个月，明显长于阴性表达者的１３.５个月，两者差异有统计学意义（Ｐ＜０.０５）。单因素分析显示，临床分期、远处转移及ＴＩＰ３０与预后相关；多因素分析显示，仅ＴＩＰ３０与预后有关（Ｐ＝０.０３０）。结论　ＴＩＰ３０可以作为一个预测ＳＣＬＣ患者术后复发、转移及预后的分子标记物。

Relationship between the expression of TIP30 and clinic-pathologic characteristics and prognosis in small cell lung cancer

Objective To explore the relationship between the expression of TIP30 and its clinic-pathologic characteristics and prognosis in small cell lung cancer（SCLC）.Methods The expression of TIP30 in 54 cases of SCLC tissues and 42 cases of para-cancerous tissues were examined by En Vision method.Results The positive rate of TIP30 was 80.95% and 46.29% in SCLC tissues and para-cancerous tissues with statistic significance（P0.05）.The expression of TIP30 protein were not correlated with gender,age and smoking condition,but correlated with clinical stage,lymph node metastasis,recurrence and distant metastasis.The median overall survival of 54 cases of SCLC was 15.4 months,and it of TIP30 positive expression cases was 26.6 months,higher than 13.5 months in negative expression cases（P0.05）.Univariate analysis showed clinical stage,distant metastasis and TIP30 influenced the survival of SCLC patients,while multivariate analysis showed TIP30 was the only factor related to the prognosis of SCLC patients（P=0.030）.Conclusion TIP30 may be used as a molecular marker to identify and predict the relapse,metastasis and prognosis of SCLC.